Next report date
Report period
Q1 2024
EPS estimate
−0.61USD
Revenue estimate
—
−104.78 MUSD
5.00 MUSD
About Adlai Nortye Ltd.
Sector
CEO
Yang Lu
Website
Headquarters
Hangzhou
Founded
2018
FIGI
BBG01HP11SV4
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
